Document Detail


Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.
MedLine Citation:
PMID:  11269779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxidized low-density lipoproteins are important in the progression of atherosclerosis. Autoantibodies against malondialdehyde-modified low-density lipoproteins have been reported to be predictive of the progression of atherosclerosis. This study sought to examine whether plasma levels of autoantibodies against oxidized low-density lipoprotein increase in the coronary circulation in patients with coronary spastic angina. The authors examined plasma antioxidized low-density lipoprotein antibody levels (activity unit values (AcU)/mL) simultaneously in the coronary sinus and the aortic root in 20 patients with coronary spastic angina, 23 patients with stable exertional angina, and 15 control subjects by measuring plasma levels of immunoglobulin G (IgG) autoantibodies against malondialdehyde-modified low-density lipoproteins by enzyme-linked immunosorbent assay. The plasma antioxidized low-density lipoprotein antibody levels (AcU/mL) in the coronary sinus increased in coronary spastic angina (38 +/- 16) compared with stable exertional angina (23 +/- 7) and control subjects (20 +/- 6) (p < or = 0.0001). The levels (AcU/mL) in the aortic root also increased in coronary spastic angina (33 +/- 12) compared with stable exertional angina (23 +/- 7) and control subjects (20 +/- 6) (p < 0.005). Furthermore, the coronary sinus-arterial differences of the levels (AcU/mL) were also higher in coronary spastic angina (5 +/- 9) than in stable exertional angina (0 +/- 6) and healthy subjects (-1 +/- 5) (p < 0.05). The generation of malondialdehyde-modified low-density lipoproteins is reported to be associated with atherothrombosis. These findings suggest that elevated levels of autoantibodies against malondialdehyde-modified oxidized low-density lipoproteins in coronary circulation are associated with the development of atherothrombosis from the progression of atherosclerosis rather than with the extent of coronary atherosclerosis in patients with coronary spastic angina.
Authors:
H Ogawa; H Soejima; K Takazoe; S Miyamoto; I Kajiwara; H Shimomura; T Sakamoto; M Yoshimura; K Kugiyama; M Kimura; H Yasue
Related Documents :
9550499 - Cholesterol lowering in the management of coronary artery disease: the clinical implica...
10712399 - Cholesterol-lowering treatment is associated with improvement in coronary vascular remo...
8775549 - Changes in apolipoproteins during the acute phase of kawasaki disease.
11828189 - Effect of controlling hypercholesterolemia on myocardial ischemia.
15680709 - Statins decrease perioperative cardiac complications in patients undergoing noncardiac ...
15771919 - Electrocardiographic events and cholesterol reduction with pravastatin in patients with...
313189 - Perioperative myocardial infarction associated with coronary artery bypass graft surger...
2437339 - Evaluation of left ventricular residual function using postextrasystolic potentiation. ...
24948359 - Ebstein's anomaly unmasked by accessory pathway ablation.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Angiology     Volume:  52     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-04-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  167-74     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto City, Japan. ogawah@kumamoto-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholine / administration & dosage,  diagnostic use
Administration, Sublingual
Adult
Aged
Angina Pectoris, Variant / blood,  diagnosis,  immunology*
Autoantibodies / immunology*
Biological Markers / blood
Coronary Angiography
Coronary Circulation / immunology*
Coronary Vessels
Diagnosis, Differential
Disease Progression
Electrocardiography
Enzyme-Linked Immunosorbent Assay
Female
Heart Catheterization
Humans
Immunoglobulin G / immunology
Injections, Intra-Arterial
Lipoproteins, LDL / immunology*
Male
Malondialdehyde / immunology
Middle Aged
Nitroglycerin / administration & dosage,  diagnostic use
Oxidation-Reduction
Vasodilator Agents / administration & dosage,  diagnostic use
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Biological Markers; 0/Immunoglobulin G; 0/Lipoproteins, LDL; 0/Vasodilator Agents; 51-84-3/Acetylcholine; 542-78-9/Malondialdehyde; 55-63-0/Nitroglycerin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring ba...
Next Document:  Microalbuminuria, pulse pressure, left ventricular hypertrophy, and myocardial ultrasonic tissue cha...